Lallemand Pharma introduces Ismigen in Poland
Oral vaccine is recommended in the prevention of COPD
Lallemand Pharma Europe and GlaxoSmithKline (GSK) have launched Ismigen in Poland.
Produced by Lallemand, based near Copenhagen, Denmark, Ismigen is a Polyvalent Mechanical Bacterial Lysate (PMBL), also described as an oral vaccine. It is recommended in the prevention of acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.
According to the latest World Health Organisation (WHO) estimates, 210 million people suffer from COPD worldwide, and 3 million people died of COPD in 2005. WHO predicts that COPD will become the third leading cause of mortality worldwide by 2030.
PMBL have also shown strong potential against bacterial infections that constitute the major complication of viral respiratory infections.
Lallemand is a privately held Canadian company specialising in yeast, bacteria and yeast derivatives for the pharmaceutical, animal nutrition, baking and winemaking industries. Its Lallemand Pharma Europe division is dedicated to the marketing and sales in Europe of drugs based on high quality polyvalent mechanical bacterial lysates.
